Best American Society Of Hematology Podcasts (2024)

1
One on One With Dr. Fred Appelbaum 26:25

1h ago26:25

26:25

In this episode, Contributing Editor Lori Muffly, MD, MS, an associate professor of medicine specializing in blood and marrow transplantation and cellular therapy at Stanford University in California, talks with Fred Appelbaum, MD, executive vice president and deputy director at the Fred Hutchinson Cancer Center in Seattle, and a professor of medic…

1
Genetic Switch System Suggests Targeting of Mutant JAK2 Reverses Myeloproliferative Neoplasms 23:49

5d ago23:49

23:49

In this episode, Contributing Editor Bethan Psaila, MD, PhD, an associate professor of hematology at the University of Oxford’s MRC Weatherall Institute of Molecular Medicine, talks with Andrew Dunbar, MD, an assistant professor and independent lab investigator at MD Anderson Cancer Center in Houston, Texas. They discuss Dr. Dunbar’s paper recently…

1
Reassessing the CLL prognostic index; ADAMTS13 conformation and risk of relapse in immune-mediated TTP; haploidentical bone marrow transplant in sickle cell disease 23:39

6d ago23:39

23:39

In this week's episode we’ll discuss the prognostic value of the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies, learn how peak ADAMTS13 activity can be used to assess ADAMTS13 conformation and risk of relapse in immune-mediated thrombotic thrombocytopenic purpura, and discuss the findings from a phase …

1
A biomarker for disease severity in Wiskott-Aldrich Syndrome; loss of Dnmt3a confers resistance to IFNα; unrelated donor selection in HSCT with PTCy 19:16

13d ago19:16

19:16

In this week's episode we'll discuss assessing risk profile in Wiskott-Aldrich Syndrome, or WAS. Then, we'll learn about how the loss of DNMT3A confers resistance to interferon-alpha in hematopoietic stem cells carrying the JAK2-V617F mutation. Finally, we'll explore unrelated donor selection for AML patients undergoing hematopoietic stem cell tran…

1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer 1:00:48

15d ago1:00:48

1:00:48

Dr Justin F Gainor from Massachusetts General Hospital in Boston and Dr Karen Reckamp from Cedars-Sinai Center in Los Angeles, California, summarize recently presented data on targeted therapy strategies for non-small cell lung cancer harboring actionable therapeutic targets.By Neil Love, MD

1
Nilotinib with or without cytarabine for Philadelphia-positive AML; thrombosis risk in Factor V Leiden and Prothrombin G20210A; ctDNA improves prognostic prediction in relapsed/refractory multiple myeloma ... 23:05

20d ago23:05

23:05

In this week's episode we’ll discuss the safety and efficacy of nilotinib with or without cytarabine in Philadelphia-positive acute lymphoblastic leukemia; learn more about thrombosis risk in double heterozygous carriers of Factor V Leiden and prothrombin G20210A and discuss the utility of circulating cell-free tumor DNA in prognostic prediction in…

1
Hemophilia prophylaxis with fitusiran vs BPA/CFC; germline NBN variants in pediatric B-ALL; Histone demethylation and cell-intrinsic immune response in AML 18:59

27d ago18:59

18:59

In this week's episode we'll learn about fitusiran prophylaxis in patients with hemophilia A or B, with or without inhibitors. Next we'll hear about new findings that heterozygous germline variants in the NBN gene that are linked to increased risk of B-cell acute lymphoblastic leukemia in children. Finally, we'll explore new insights on the histone…

1
Effects of voxelotor on cerebral blood flow in pediatric sickle cell disease; thrombosis in Vexas syndrome; response to tyrosine kinase inhibitors in ABL-class acute lymphoblastic leukemia 22:26

1M ago22:26

22:26

In this week's episode we’ll discuss the effects of voxelotor on cerebral blood flow in pediatric sickle cell disease, learn more about venous and arterial thrombosis in patients with Vexas syndrome, and discuss differential sensitivity to tyrosine kinase inhibitors in ABL-class acute lymphoblastic leukemia. Featured Articles: The influence of voxe…

1
Stamping out high-risk myeloma with D-KRd and tandem transplant; plasmin-cleaved VWF in microthrombosis; SCD plasma sensitizes iPSC-derived sensory neurons 19:40

1M ago19:40

19:40

In this week's podcast we'll discuss another step forward in stamping out high-risk myeloma. Then we'll hear about the plasmin-cleaved von Willebrand factor, or VWF, in microthrombosis. Finally we'll hear about new insights into the origins of sickle cell pain. Featured Articles: Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem…

1
Celebrating Pride Month with Career Development Advice for LGBTQ+ Hematology Trainees 21:14

2M ago21:14

21:14

In this Pride Month-themed episode of Hematopoiesis, Drs. Emily Liang, Ajay Major, Michael Hochman, and Shail Maingi discuss career development, community building, and navigating the workforce for LGBTQ+ trainees in hematology.By American Society of Hematology

1
Allogeneic transplant in first remission for post-induction molecular MRD; circulating HSPCs actively participate in human hematopoiesis; let-7 miRNAs repress HIC2 to regulate BCL11A transcription and ... 21:44

2M ago21:44

21:44

In this week's episode we’ll discuss the utility of MRD in identifying patients with NPM1 AML who benefit from allogeneic transplant in first remission, learn more about the contribution of circulating hematopoietic stem/progenitor cell subsets to human hematopoietic hemostasis, and discuss the role of Let-7 miRNAs in regulation of BCL11A transcrip…

1
Venous Thromboembolism Risk Markers and Discontinuing Combined Hormonal Contraceptives 25:41

2M ago25:41

25:41

In this episode, Contributing Editor Samuel Wilson, MD, an assistant professor of hematology at the University of North Carolina, Chapel Hill, talks with Marc Blondon, MD, an attending physician in the division of angiology and hemostasis with the University Hospitals of Geneva (Switzerland). They talk about a paper co-authored by Dr. Blondon title…

1
ADAMTS13 recovery in caplacizumab-treated TTP; inhibition of venetoclax-resistant BCL2 variants with sonrotoclax; genomic insights from Castleman disease in twins 19:10

2M ago19:10

19:10

In this week's epside we'll learn about ADAMTS recovery after caplacizumab therapy in patients with immune thrombotic thrombocytopenic purpura. Then, we'll hear about preclinical characterization of sonrotoclax, a potential second-generation BCL2 inhibitor. Finally we'll hear about new insights into the etiology of Castleman disease where researche…

1
Durable response after tisa-cel in adults with relapsed/refractory follicular lymphoma; high microRNA-145 plasma levels indicate decreased risk of VTE; epigenetic/immunogenetic signature in the prediction ... 23:49

2M ago23:49

23:49

In this week's episode, we’ll discuss the findings from a study assessing responses after treatment with tisagenlecleucel [LM1] in adults with relapsed/refractory follicular lymphoma, learn more about the association between high microRNA-145 plasma levels and decreased risk of future incident venous thromboembolism, and discuss how epigenetic and …

1
Gut microbiota exploitation by CPX-351 in AML; optimizing anti-myeloma immunity for ASCT; which pediatric ITP patients will develop lupus? 19:00

2M ago19:00

19:00

In this week's episode, we'll discuss gut microbiota exploitation by CPX-351 in acute myeloid leukemia. Then we'll learn about optimizing anti-myeloma immunity. New research shows that regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation. Finally we'll discuss among pediatric patients wi…

1
Growing the Next Generation of Hematologists 20:14

2M ago20:14

20:14

In this episode, Editor-in-Chief Shaji Kumar, MD, a professor of medicine at Mayo Clinic in Rochester, Minnesota, talks with Leslie Ellis, MD, a professor of internal medicine at Atrium Health Wake Forest Baptist in Winston Salem, North Carolina. They discuss the ASH Ambassador Program, which is designed to support the recruitment and retention of …

1
Jak2V617F clonal hematopoiesis promotes arterial thrombosis; Staphylococcus aureus infection in Sézary syndrome; clinical features of RAC2-related immunodeficiency 26:18

2M ago26:18

26:18

In this week's episode we’ll discuss the mechanism by which Jak2V617F clonal hematopoiesis promotes arterial thrombosis, discuss how Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome, and learn more about the clinical and functional features of RAC2-related immunodeficiency. Featured Articles: Jak2V617F clonal hemat…

1
Oncology Today with Dr Neil Love: The Emerging Role of B7-H3-Targeted Antibody-Drug Conjugates 32:24

3M ago32:24

32:24

Dr Manish Patel from the Florida Cancer Specialists & Research Institute in Sarasota, Florida, discusses drug development, early-phase clinical trials and the emerging field of B7-H3-targeted antibody-drug conjugates for solid tumors.By Neil Love, MD

1
Molecular mimicry in aplastic anemia; emicizumab prophylaxis in infants with hemophilia; hydroxyurea reduces infections in SCA 19:54

3M ago19:54

19:54

In this week's episode we'll discuss molecular mimicry in aplastic anemia, novel experiments show that antigens associated with viral infections can mimic epitopes presented on hematopoietic progenitor cells. Then, we'll learn about prophylaxis with subcutaneous emicizumab in infants with hemophilia. Finally we'll see how hydroxyurea is associated …

1
Review Series on the Influence of the Tumor Microenvironment on the Pathogenesis of B-Cell Lymphomas 32:05

3M ago32:05

32:05

In this bonus episode of Blood Podcast, Associate Editor, Dr. Freda Stevenson is joined by Drs. Karin Tarte, Andrea Radtke, and Leandro Cerchietti to discuss the Review Series on the influence of the tumor microenvironment on the pathogenesis of B-cell lymphomas. Find the full review series in Blood Journal volume 143 issue 12.…

1
Free light chain mass spectrometry in diagnosis and monitoring of AL amyloidosis; T cells of AML patients in remission have distinct RNA signatures; and protective effect of ADAMTS13 in sickle cell mice ... 22:34

3M ago22:34

22:34

In this week's episode we’ll discuss the findings from a study assessing the utility of free light chain mass spectrometry in AL amyloidosis, learn more about distinct single-cell RNA-sequencing signatures of bone marrow T cells of AML patients in remission after an allogeneic stem cell transplant, and discuss why von Willebrand factor clearance is…

1
Women in Hematology 26:39

3M ago26:39

26:39

In this episode, Tamara Dunn, MD, a clinical associate professor of medicine in the division of hematology at Stanford University in Stanford, California, and co-chair of ASH’s Women in Hematology Working Group, hosts a conversation with Toyosi Onwuemene, MD, an associate professor of medicine, specializing in hemostasis/thrombosis, at Duke Univers…

1
Eculizumab in transplant-associated thrombotic microangiopathy; reclassifying malignant monocytosis; targeting tissue factor in antiphospholipid syndrome 20:50

3M ago20:50

20:50

In this week's episode we'll discuss eculizumab in stem cell transplant-associated thrombotic microangiopathy. Then, we'll learn about reclassifying malignant monocytosis, these newly classified cases have distinct mutational and transcriptional profiles. Finally, we'll hear about targeting the tissue factor coagulation initiation complex prevents …

1
Oncology Today with Dr Neil Love: Promising Therapeutic Strategies for Patients with Progressive Metastatic Non-Small Cell Lung Cancer 1:02:57

3M ago1:02:57

1:02:57

Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data with antibody-drug conjugates with established and investigational targets in patients with non-small cell lung cancer.By Neil Love, MD

1
Four Is Better Than Three: Will We Finally Agree? 23:18

3M ago23:18

23:18

In this episode, Contributing Editor Ajai Chari, MD, a professor of clinical medicine and director of the myeloma program at the University of California San Francisco, talks with Pieter Sonneveld, MD, PhD, a professor of hematology at the Erasmus University of Rotterdam in the Netherlands. They discuss Dr. Sonneveld’s recent paper, “Daratumumab, B…

1
Identification of rare relapse-initiating stem cells post-transplantation; interferon α impairs erythropoiesis in sickle cell disease; TNFα promotes clonal dominance of KIT D816V+ cells in mastocytosis ... 22:48

3M ago22:48

22:48

In this week's episode we’ll learn more about rare relapse-initiating stem cells in patients with MDS or AML in complete remission post-transplantation, discuss the role of interferon α in erythropoiesis in sickle cell disease, and learn more about how TNFα promotes clonal dominance of KIT D816V+ cells in mastocytosis.…

1
How PAR2 signaling drives thrombo-inflammation; pretransfusion hemoglobin levels linked to survival in beta-thalassemia; etoposide is better than its reputation in primary HLH 17:48

4M ago17:48

17:48

In this week's episode we'll discuss PAR2-biased signaling in thrombo-inflammation. Then, we'll learn about how hemoglobin levels are linked to survival in transfusion-dependent beta-thalassemia. Finally we'll hear about how etoposide is better than its reputation in primary HLH—hemophagocytic lymphohistiocytosis. Symptomatic patients treated with …

1
Brentuximab vedotin plus dacarbazine or nivolumab in classical Hodgkin lymphoma; loss of CD20 causes resistance to mosunetuzumab in r/r B-cell lymphomas; trogocytosis as a driver of RBC antigen loss 23:02

4M ago23:02

23:02

In this week's episode we’ll discuss the findings from a prospective trial of brentuximab vedotin with dacarbazine or nivolumab in older patients with classical Hodgkin lymphoma, learn more about CD20 antigen loss as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas, and discuss the role of trogocytosis in red blood…

1
CAR T cells plus ibrutinib in relapsed/refractory MCL; targeting SGF29 in AML; diffusion-limited oxygen release from stored blood 18:50

4M ago18:50

18:50

In this week's episode we'll discuss CAR T cells plus ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma. Next, we'll learn about a new SAGA for acute myeloid leukemia. Finally, we'll hear about new evidence that oxygen delivery to tissues can become diffusion-limited during perfusion with stored blood.…

1
Long-term outcomes of pulmonary embolism in children and adolescents; hereditary angioedema caused by a methionine-379 to lysine substitution in kininogens; predictors of loss of MRD negativity in multiple ... 25:07

4M ago25:07

25:07

In this week's episode we’ll report on the findings from a study evaluating the long-term outcomes of pulmonary embolism in children and adolescents, discuss a new mechanism for hereditary angioedema caused by a methionine-379 to lysine substitution in kininogens, and learn more about predictors of unsustained minimal residual disease negativity in…

1
Extended follow-up of axi-cel in indolent NHL; platelets help clear senescent RBCs; novel risk stratification strategy for CNS lymphoma 18:58

5M ago18:58

18:58

In this week's episode we'll discuss extended follow-up from the ZUMA-5 trial of axicabtagene ciloleucel, or axi-cel. Then we'll learn about the role of platelets in binding and clearing senescent red blood cells. Finally, we'll hear about a new risk stratification strategy for lymphomas of the central nervous system, or CNS.…

1
Lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma; reciprocal stabilization of coagulation factor XIII-A and -B subunits; inotuzumab ozogamicin for MRD in ALL 22:26

5M ago22:26

22:26

In this week's episode we’ll discuss the findings from a two-year follow-up study of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma, learn more about how reciprocal stabilization of coagulation factor XIII-A and -B subunits influences plasma FXIII concentration, and discuss the findings from a phase 2 study of inotuzumab o…

1
Multiple Myeloma in Underrepresented Populations: Treatment Considerations 24:04

5M ago24:04

24:04

Dr. Azam Farooqui (@azamfarooqui ) and Dr. Monique Hartley-Brown (@DrMHB1) discuss therapeutic considerations regarding current and emerging agents for patients with multiple myeloma from underrepresented racial and ethnic groups. Coming Soon! Prepare to enhance your knowledge through the IMPACT II online learning module on ASH Academy On Demand! P…

1
Multiple Myeloma in Underrepresented Populations: Survival Outcomes 18:54

5M ago18:54

18:54

Dr. Azam Farooqui (@azamfarooqui )and Dr. Sikander Ailawadhi answer the question: Why do we need earlier diagnosis and intervention in patients with multiple myeloma from underrepresented racial and ethnic groups? Coming Soon! Prepare to enhance your knowledge through the IMPACT II online learning module on ASH Academy On Demand! Participants will …

1
Multiple Myeloma in Underrepresented Populations: Clinical Risk 16:42

5M ago16:42

16:42

Dr. Azam Farooqui (@azamfarooqui) and Dr. Urvi Shah (@UrviShahMD) identify factors that impact outcomes for patients with multiple myeloma from underrepresented racial and ethnic groups. Coming Soon! Prepare to enhance your knowledge through the IMPACT II online learning module on ASH Academy On Demand! Participants will develop an increased abilit…

1
IMPACT II: Impacting Multiple Myeloma in All CommuniTies 1:33

5M ago1:33

1:33

Season 2: IMPACT II: Impacting Multiple Myeloma in All CommuniTies Unlock insights into the treatment of multiple myeloma within underrepresented racial and ethnic populations with this series of three enlightening podcast episodes. Join experts from both academic and community oncology settings as they dive into critical aspects of clinical risk, …

1
Toward Equity in Access for ALL 26:42

5M ago26:42

26:42

In this episode, Contributing Editor Lori Muffly, MD, an associate professor of medicine specializing in blood and marrow transplantation and cellular therapies at Stanford University in California, talks with Roberta Demichelis, MD, an assistant professor in the department of hematology and oncology at the Salvador Zubirán National Institute of He…

1
Maternal anticancer drug exposure and leukemia; PIEZO1-TMEM16F coupling in hereditary xerocytosis; NPM1 MRD during venetoclax therapy in NPM1-mutated AML 18:12

5M ago18:12

18:12

In this week’s episode, we’ll discuss the association between occupational exposure to anticancer agents in a parent and subsequent cancer in a child. Then we’ll learn about deciphering and disrupting the activation of PIEZO1 in hereditary xerocytosis. Finally, we’ll hear about the assessment of measurable residual disease, or MRD, in patients with…

1
TCRαβ/CD19-cell depleted haploHSCT for pediatric leukemia; malignancy-associated hemophagocytic lymphohistiocytosis in Sweden; the bone marrow as the primary site of thrombopoiesis 21:55

5M ago21:55

21:55

In this week's episode we’ll discuss the findings from a prospective trial of TCRαβ/CD19-cell depleted HLA-haploidentical transplantation to treat pediatric acute leukemia, learn more about the incidence, clinical characteristics, and survival of malignancy-associated hemophagocytic lymphohistiocytosis in Sweden, and discuss the bone marrow as the …

1
Fibrin polymerization and thrombosis; preventing CD19-negative relapse after CAR T-cell therapy in ALL; and impact of aberrant FUS condensates on HSC aging 18:00

6M ago18:00

18:00

In this week's episode we’ll explore the role of fibrinogen polymerization in thrombosis. Then, we’ll discuss preventing CD19-negative relapse after CAR T-cell therapy in acute lymphoblastic leukemia. Finally, we’ll learn how increased levels of the RNA-binding protein FUS has been identified as an effector of hematopoietic stem cell aging.…

1
CD24Fc for prevention of GVHD; origins of active EBV disease; the role of PF4 in platelet activation 21:45

6M ago21:45

21:45

In this week's episode we’ll discuss the findings from a phase 2 study of CD24Fc for prevention of graft-versus-host disease, learn more about the origins of chronic active Epstein-Barr virus disease, and discuss the role of PF4 in platelet activation.By American Society of Hematology

1
Profiling a new VITT-like disorder; real-world outcomes of tafasitamab and lenalidomide in LBCL; and spatial mapping of human hematopoiesis 18:39

6M ago18:39

18:39

In this week's episode we'll uncover the clinical and pathological profile of a new disorder similar to VITT, or vaccine-induced thrombocytopenia and thrombosis. Then, we'll discuss real-world outcomes in patients with large B-cell lymphoma treated with tafasitamab and lenalidomide. Finally we'll learn about how advances in technology help unravel …

1
A natural history of familial platelet disorder with myeloid malignancy; HEXIM1 as an essential transcription regulator in erythropoiesis; residual disease predicts relapse in CML patients 21:53

6M ago21:53

21:53

In this week's episode we’ll discuss the findings from a natural history study of patients with familial platelet disorder with myeloid malignancy, learn more about the role of HEXIM1 as an essential transcription regulator in human erythropoiesis, and discuss the utility of residual disease as a predictor of relapse in CML patients stopping TKI th…

1
ETP and MRD for risk assessment in T-ALL; allogeneic HCT outcomes in CGD; effects of pathogenic/likely pathogenic variants in inherited hemostasis disorders 20:26

7M ago20:26

20:26

On today's episode we’ll discuss the prognostic significance of the ETP phenotype in children with T-cell ALL, address knowledge gaps in the management of chronic granulomatous disease and learn about the effects of pathogenic and likely pathogenic variants for inherited hemostasis disorders.By American Society of Hematology

1
Implications of Recent Data Sets for the Current and Future Management of Lung Cancer 1:30:16

7M ago1:30:16

1:30:16

Dr Luis Paz-Ares from the National Oncology Research Center in Madrid, Spain, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, and Dr David R Spigel from the Sarah Cannon Research Institute in Nashville, Tennessee, discuss key presentations from the 2023 ESMO Congress for the management of lung cancer.…

1
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML; inhibition of PLK4 in TP53-mutated AML; the role of CD44 in Plasmodium falciparum infection 22:34

7M ago22:34

22:34

On today's episode we’ll discuss the findings from a phase 2 study of sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML, learn more about the inhibition of PLK4 in TP53-mutated AML, and discuss the role of CD44 in Plasmodium falciparum infection.By American Society of Hematology

1
High-risk cytogenetics in solitary bone plasmacytomas; complement activation in vaso-occlusive pain episodes; platelet reactivity to predict thrombotic disease risk 18:32

7M ago18:32

18:32

On today’s podcast we'll discuss high-risk cytogenetic abnormalities in solitary bone plasmacytomas. Then, we'll consider complement activation in vaso-occlusive pain episodes and how targeting C5a generation inhibited those effects. Finally we'll explore the genetics of platelet reactivity and how researchers used this data to develop a genetic sc…

1
The Brilliant Success of Blinatumomab for Babies With Acute Lymphoblastic Leukemia 16:13

7M ago16:13

16:13

In this episode, Contributing Editor Sarah Tasian, MD, associate professor at the University of Pennsylvania School of Medicine and chief of the hematologic malignancies program at the Children’s Hospital of Philadelphia, talks with Rob Pieters, MD, the chief medical officer at the Princess Maxima Center for Pediatric Oncology and professor of pedi…

1
Very long-term follow-up of FCR therapy for CLL, risk assessment of KMT2A-rearranged B-cell precursor ALL in adults; anti-myeloma therapy using antibodies armed with B-BiTEs 24:38

7M ago24:38

24:38

On this week's episode we’ll discuss the findings from a long-term follow up study of fludarabine, cyclophosphamide, and rituximab in IGHV-mutated CLL, learn more about the impact of genetic alterations and minimal residual disease in adults with KMT2A-rearranged B-cell precursor ALL, and discuss a pre-clinical study of reinforced immunotherapy for…

1
Fractionated gemtuzumab ozagamicin Dosing in Elderly AML Patients; Loss-of-function of ENT3 drives histiocytosis; Alternative splicing of CD20 5’-UTR in B-lymphomas 19:47

7M ago19:47

19:47

In this week's episode we'll discuss if fractionated dosing of gemtuzumab ozogamicin provide additional benefit over a single dose in older adults with AML. Then, we'll consider how the loss-of-function of ENT3 drives histiocytosis. Researchers describe a novel pathway leading to histiocytosis that involves hyperactivation of TLR-MAPKinase signalin…

Podcasts Worth a Listen

American Society Of Hematology Podcasts

Podcasts Worth a Listen

Quick Reference Guide